Evidence map›Paper›PMID 40529182›Full record

ArticleComputational and structural biotechnology journal2025

High-resolution accurate mass- mass spectrometry based- untargeted metabolomics: Reproducibility and detection power across data-dependent acquisition, data-independent acquisition, and AcquireX.

Hanane El Boudlali, Laura Lehmicke, Uta Ceglarek

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Phytochemical Profile and Antioxidant Potential ofAntioxidants (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Bridging bioactive metabolites ofFrontiers in pharmacology · 2026
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hanane El BoudlaliClinical Mass Spectrometry Section, Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig Medical Center, Liebig Street 27, Leipzig D-04103, Germany.
Laura LehmickeClinical Mass Spectrometry Section, Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig Medical Center, Liebig Street 27, Leipzig D-04103, Germany.
Uta CeglarekClinical Mass Spectrometry Section, Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig Medical Center, Liebig Street 27, Leipzig D-04103, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Untargeted metabolomics aims at the unbiased metabolic profiling and biomarker discovery but requires methods with high sensitivity and reproducibility. Here, we compare three acquisition modes-Data-Dependent Acquisition (DDA), Data-Independent Acquisition (DIA), and AcquireX -to evaluate performance and reproducibility in detecting low-abundance metabolites in a complex matrix. A system suitability test (SST) based on 14 eicosanoid standards was implemented to evaluate the suitability of our instrumental setup prior to conducting untargeted metabolomics analyses and monitor long-term system performance. Bovine liver total Lipid Extract (TLE) was spiked with decreasing levels (10-0.01 ng/mL) of the eicosanoid standard mix (StdMix) to compare the detection power of each mode. Reproducibility was evaluated over three independent measurements, spaced one week apart. Chromatographic separation was performed on a C18-Kinetex Core-Shell column and HRAM-MS/MS data were acquired using an Orbitrap Exploris 480. DIA detected and identified the highest number of metabolic features, (averaging 1036 metabolic features over three measurements), followed by DDA (18 % fewer) and AcquireX (37 % fewer). Moreover, DIA demonstrated superior reproducibility, with a coefficient of variance of 10 % across detected compounds over three measurements, compared to 17 % for DDA and 15 % for AcquireX. DIA further exhibited better compound identification consistency, with 61 % overlap between two days, compared to DDA (43 %) and AcquireX (50 %). DIA reproduced fragmentation spectra patterns with high consistency, contributing to higher reproducibility in compound identification. DIA showed the best detection power for all spiking eicosanoids at 10 and 1 ng/mL in TLE matrix. At low spiking levels, 0.1 and 0.01 ng/mL, a general cut-off was observed for the three acquisition modes. None of this assessed acquisition modes was able to detect and/or identify eicosanoids at physiologically relevant concentrations, explaining their frequent omission in routine untargeted analyses.

Indexed as

AcquireXDDAdetection powerDIAreproducibility

Identifiers

PMID40529182
PMCPMC12173630

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.